Manuel Monreal/X
Aug 31, 2025, 07:05
RIETE Registry Data: Manuel Monreal on VTE vs. Bleeding Risks in Cancer Patients
Manuel Monreal, coordinator of the RIETE registry, posted on X:
”The risk of the composite of fatal PE or recurrent VTE within 90 days is much higher than major bleeding in lung, breast, hematologic or pancreatic cancers
No major differences in GU or CI cancers
Should all cancer patients with acute VTE receive the same treatment strategy?”
Find it here.
Title: Variation in Venous Thromboembolism Outcomes Based on Primary Cancer Site: A RIETE Registry Analysis
Authors: Javier Trujillo-Santos, Cihan Ay, Behnood Bikdeli, David Jiménez, Aurora Villalobos, Luciano López-Jiménez, Montserrat Pérez-Pinar, Javier Pagán-Escribano, Maurizio Ciammaichella, Manuel Monreal
Stay updated with Hemostasis Today.
Aurora Villalobos
Behnood Bikdeli
Bleeding Risk
cancer
Cihan Ay
David Jimenez
Hematology
Hemostasis Today
Javier Pagán-Escribano
Javier Trujillo-Santos
Luciano López-Jiménez
Manuel Monreal
Maurizio Ciammaichella
Montserrat Pérez-Pinar
PE
Pulmonary embolism
RIETE registry
venous thromboembolism (VTE)
-
Sep 17, 2026, 13:09Mehak Trehan: New Perspectives on Anemia Management in CKD
-
Sep 17, 2026, 10:08WFH 2027 Comprehensive Care Summit Opens Abstract Submissions – World Federation of Hemophilia
-
Sep 17, 2026, 09:56Marianne Yee: MySCDstory Expands Access to Multilingual Sickle Cell Education
-
Sep 17, 2026, 09:36Enewa Onoja: Platelet Satellitism Phenomenon, Three Misleading Counts
-
Sep 17, 2026, 09:22Emmanuel J Favaloro: Hemostasis and Thrombosis in Exercise and Athletes
-
Sep 17, 2026, 09:18Updated Iron Deficiency Diagnostic Guidelines – American Society of Hematology
-
Sep 17, 2026, 09:14Angela Weyand: ASH 2026 Iron Deficiency Guidelines
-
Sep 17, 2026, 08:18Anirban Sen Gupta: From Flow to Clot Insights Into Hemostasis and Thrombosis
-
Sep 17, 2026, 08:03Aya Sherif: HEMO COP – Building a Collaborative Future for Hemophilia Care